Sangamo BioSciences, Inc. was founded in 1995 and is based in Richmond, California. Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company’s ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences, Inc. involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson's disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC;Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; and Medarex, Inc., as well as has research agreements with Amgen Inc., Novo Nordisk Inc., Novartis A/G, and Kirin Brewery Company.

Simplexity Health (formerly Cell Tech International) hopes that the algae growing in the fountain of youth is the secret. More specifically, the company scrapes up Aphanizomenon flos-aquae, a type of blue-green algae, out of Upper Klamath Lake, and stirs it into nutritional supplements, body care products, and nutrition bars. Calling it Super Blue Green Algae, the company's product line includes digestive aids, weight loss supplements, antioxidants, and powdered drink mixes. Simplexity Health sells its products through a multi-level, direct marketing program using a network of independent associates.

The Mentholatum Company's best-known products, Mentholatum Deep Heating Rub, but they can probably find another of the company's bestsellers in their medicine cabinets -- Oxy Pads. The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, makes OTC products to relieve a variety of common ailments, including acne, cold sores, aches and pains, and chest congestion. In addition to the Oxy and Mentholatum brands, the firm sells its products under the WellPatch, Rohto, Fletcher's, Red Cross, Natural Ice, and Softlips monikers. ROHTO's Mentholatum companies have operations in more than a dozen countries and sells products in more than 150 countries.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Teva Pharmaceutical Industries Limited company was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

Purdue Pharma L.P. company specializes in developing, manufacturing, and marketing sustained-release and long-acting treatments for chronic and severe pain. Its opioid drugs for pain relief include controlled-release analgesics OxyContin (a version of oxycodone), Ryzolt (tramadol), and morphine drug MS Contin. The company continues to develop and commercialize new products through alliances with such companies as Transcept and Labopharm. Purdue also sells a number of non-prescription products including topical antiseptic Betadine and the Colace and Senokot lines of laxatives. Purdue Pharma operates in the US.

Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders.

Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.